Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay

Transplantation

Volumn 91, Issue 5, 2011, Pages 527-535

  Couzi, Lionel ^a,b,c   Araujo, Caroline ^a   Guidicelli, Gwendaline ^a   Bachelet, Thomas ^a   Moreau, Karine ^a   Morel, Delphine ^a   Robert, Grégoire ^a,c   Wallerand, Hervé ^a,c   Moreau, Jean François ^a,b,c   Taupin, Jean Luc ^a,b,c   Merville, Pierre ^a,b,c  

^a HÔPITAL PELLEGRIN   (France)

^b CNRS Bordeaux Segalen University   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Acute rejection; Crossmatch; DSA; Kidney transplantation

Indexed keywords

HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; B LYMPHOCYTE; BLOOD GROUP TYPING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOASSAY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 79952184151     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31820794bb     Document Type: Article

References (38)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
2. Johnson AH, Rossen RD, Butler WT. Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: Identification of low levels of pre-formed antibodies in accelerated allograft rejection. Tissue Antigens 1972; 2: 215.
3. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donorreactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3: 1488.
4. Kerman RH, Susskind B, Buyse I, et al. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation 1999; 68: 1855.
5. Ogura K, Terasaki PI, Johnson C, et al. The significance of a positive flow cytometry crossmatch test in primary kidney transplantation. Transplantation 1993; 56: 294.
6. Chapman JR, Taylor CJ, Ting A, et al. Immunoglobulin class and specificity of antibodies causing positive T cell crossmatches. Relationship to renal transplant outcome. Transplantation 1986; 42: 608.
7. Karuppan SS, Lindholm A, Moller E. Characterization and significance of donor-reactive B cell antibodies in current sera of kidney transplant patients. Transplantation 1990; 49: 510.
8. Karuppan SS, Lindholm A, Moller E. Fewer acute rejection episodes and improved outcome in kidney-transplanted patients with selection criteria based on crossmatching. Transplantation 1992; 53: 666.
9. Karuppan SS, Ohlman S, Moller E. The occurrence of cytotoxic and non-complement-fixing antibodies in the crossmatch serum of patients with early acute rejection episodes. Transplantation 1992; 54: 839.
10. Suciu-Foca N, Reed E, D'Agati VD, et al. Soluble HLA antigens, anti- HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients. Transplantation 1991; 51: 593.
11. Taylor CJ, Chapman JR, Ting A, et al. Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome. Transplantation 1989; 48: 953.
12. Taylor CJ, Kosmoliaptsis V, Summers DM, et al. Back to the future: Application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol 2009; 70: 563.
13. Vlad G, Ho EK, Vasilescu ER, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009; 70: 589.
14. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684.
15. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: Incidence and correlations. Am J Transplant 2009; 9: 1826.
16. Pollinger HS, Stegall MD, Gloor JM, et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007; 7: 857.
17. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody.AmJ Transplant 2006; 6: 346.
18. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 2006; 6: 2307.
19. Claas FH, Witvliet MD, Duquesnoy RJ, et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome. Transplantation 2004; 78: 190.
20. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.
21. Amico P, Honger G, Mayr M, et al. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681.
22. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
23. Everly MJ, Everly JJ, Arend LJ, et al. Reducing De novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
24. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561.
25. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibodymediated rejection in positive crossmatch renal allografts.AmJ Transplant 2007; 7: 576.
26. Anglicheau D, Loupy A, Suberbielle C, et al. Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: A pilot study. Am J Transplant 2007; 7: 1185.
27. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124.
28. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324.
29. Patel AM, Pancoska C, Mulgaonkar S, et al. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007; 7: 2371.
30. Gupta A, Iveson V, Varagunam M, et al. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: Are they relevant? Transplantation 2008; 85: 1200.
31. Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86: 820.
32. Eng HS, Bennett G, Tsiopelas E, et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008; 8: 2335.
33. Kosmoliaptsis V, Bradley JA, Peacock S, et al. Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies. Transplantation 2009; 87: 813.
34. Kosmoliaptsis V, O'Rourke C, Bradley JA, et al. Improved Luminexbased human leukocyte antigen-specific antibody screening using dithiothreitol-treated sera. Hum Immunol 2010; 71: 45.
35. van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85: 1086.
36. Aubert V, Venetz JP, Pantaleo G, et al. Are all donor-specific antibodies detected by solid-phase assay before transplantation clinically relevant? Transplantation 2009; 87: 1897.
37. Limaye S, O'Kelly P, Harmon G, et al. Improved graft survival in highly sensitized patients undergoing renal transplantation after the introduction of a clinically validated flow cytometry crossmatch. Transplantation 2009; 87: 1052.
38. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.